Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases

Minerva Gastroenterologica e Dietologica

Volumn 51, Issue 2, 2005, Pages 179-186

  Pozzi, M ^a,c   Redaelli, E ^a   Ratti, L ^a   Poli, G ^a   Guidi, C ^a   Milanese, M ^a   Calchera, I ^a   Mancia, G ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Center of Clinical Physiology and Hypertension   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

Diastolic dysfunction; Echocardiography; Hepatitis C virus; Postviral cirrhosis

Indexed keywords

ALCOHOL; ALDOSTERONE; ANTIVIRUS AGENT;

ALCOHOLIC CARDIOMYOPATHY; ARTICLE; BILOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART LEFT VENTRICLE PERFORMANCE; HEART LEFT VENTRICLE WALL; HEART VENTRICLE REMODELING; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; SYMPTOMATOLOGY; AGED; CHEMICALLY INDUCED DISORDER; DIASTOLE; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEPATITIS C; HOSPITALIZATION; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; TIME; VIROLOGY;

AGED; ANTIVIRAL AGENTS; DIASTOLE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION, PORTAL; HYPERTROPHY, LEFT VENTRICULAR; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 26944446642     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953;32: 1025-33.
2. Bernardi M, Trevisani F, Santini C, De Palma R, Gasbarrini G. Aldosterone related blood volume expansion in cirrhosis before and during the early phase of ascites formation. Gut 1983;24:761-6.
3. Finucci G, Desideri A, Sacerdoti D, Bolognesi M, Merkel C, Angeli P et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996;31:279-84.
4. Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997;26:1131-7.
5. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 1999; 97:259-67.
6. De BK, Majumdar D, Das D, Biswas PK, Mandal SK, Ray S et al. Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis. J Hepatol 2003;39:315-9.
7. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996;24:451-9.
8. Piano MR. Alcohol and heart failure. J Card Fail 2002;8:239-46.
9. Moller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001;36: 785-94.
10. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
11. Valeriano V, Funaro S, Lionetti R, Riggio O, Pulcinelli G, Fiore P et al. Modification of cardiac function in cirrhotic patients with and without ascites. Am J Gastroenterol 2000;95:3200-5.
12. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
13. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
14. Triulzi MO, Castini D, Ornaghi M, Vitolo E. Effects of preload reduction on mitral flow velocity pattern in normal subjects. Am J Cardiol 1990;66:995-1001.
15. Devereux RB, Pini R, Aurigemma GP, Roman MJ. Measurement of left ventricular mass: methodology and expertise. J Hypertens 1997;15:801-9.
16. Ghanem WM, Murin J, Sleiman O, Bulas J, Jaber J, Mikes P et al. Is left ventricular hypertrophy a risk factor in hypertensive patients? Bratisl Lek Listy 2002; 103:215-22.
17. Yamada H, Goh PP, Sun JP, Odabashian J, Garcia MJ, Thomas JD et al. Prevalence of left ventricular diastolic dysfunction by Doppler echocardiography: clinical application of the Canadian consensus guidelines. J Am Soc Echocardiogr 2002;15 (10 Pt 2):1238-44.
18. de Simone G. Clinical value of diastolic dysfunction in hypertension. J Hypertens 2002;20:2309-10.
19. Maurer MS, Spevack D, Burkhoff D, Kronzon I. Diastolic dysfunction: can it be diagnosed by Doppler echocardiography? J Am Coll Cardiol 2004;44:1543-9.
20. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 1958;24:358-67.
21. Liu H, Song D, Lee SS. Cirrhotic cardiomyopathy. Gastroenterol Clin Biol 2002;26:842-7.
22. van Obbergh L, Vallieres Y, Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J Hepatol 1996;24:747-52.
23. Inserte J, Perello A, Agullo L, Ruiz-Meana M, Schluter KD, Escalona N et al. Left ventricular hypertrophy in rats with biliary cirrhosis. Hepatology 2003;38:589-98.
24. Lunseth JH, Olmstead EG, Abboud F. A study of heart disease in one hundred eight hospitalized patients dying with portal cirrhosis. AMA Arch Intern Med 1958;102:405-13.
25. Claypool JG, Delp M, Lin TK. Hemodynamic studies in patients with Laennec's cirrhosis. Am J Med Sci 1957;234:48-55.
26. Gould L, Shariff M, Zahir M, Di Lieto M. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest 1969;48:860-8.
27. Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 1974;49: 754-60.
28. Rubin E. Alcoholic myopathy in heart and skeletal muscle. N Engl J Med 1979;301:28-33.
29. Bernardi M, Di Marco C, Trevisani F, De Collibus C, Fornale L, Baraldini M et al. The hemodynamic status of preascitic cirrhosis: an evaluation under steady-state conditions and after postural change. Hepatology 1992;16:341-6.
30. Bernardi M, Trevisani F, Santini C, Zoli G, Baraldini M, Ligabue A et al. Plasma norepinephrine, weak neurotransmitters, and renin activity during active tilting in liver cirrhosis: relationship with cardiovascular homeostasis and renal function. Hepatology 1983;3:56-64.
31. Henriksen JH, Moller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol 1998;29:328-41.
32. Bayley TJ, Segel N, Bishop JM. THE circulatory changes in patients with cirrhosis of the liver at rest and during exercise. Clin Sci 1964;26:227-35.
33. Lunzer MR, Newman SP, Bernard AG, Manghani KK, Sherlock SP, Ginsburg J. Impaired cardiovascular responsiveness in liver disease. Lancet 1975;2:382-5.
34. Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baraldini M et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol 1991;12:207-16.
35. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995;22:326-32.
36. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001;49:268-75.
37. Pozzi M, Grassi G, Ratti L, Favini G, Dell'oro R, Redaelli E et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral Child A cirrhosis. Am J Gastroenterol 2005;5:1110-6.
38. La Villa G, Barletta G, Romanelli RG, Laffi G, Del Bene R, Vizzutti F et al. Cardiovascular effects of canrenone in patients with preascitic cirrhosis. Hepatology 2002;35:1441-8.
39. Teragaki M, Nishiguchi S, Takeuchi K, Yoshiyama M, Akioka K, Yoshikawa J. Prevalence of hepatitis C virus infection among patients with hypertrophic cardiomyopathy. Heart Vessels 2003;18:167-70.
40. Matsumori A, Ohashi N, Hasegawa K, Sasayama S, Eto T, Imaizumi T et al. Hepatitis C virus infection and heart diseases: a multicenter study in Japan. Jpn Circ J 1998;62:389-91.
41. Matsumori A, Matoba Y, Nishio R, Shioi T, Ono K, Sasayama S. Detection of hepatitis C virus RNA from the heart of patients with hypertrophic cardiomyopathy. Biochem Biophys Res Commun 1996;222:678-82.
42. Prati D, Poli F, Farma E, Picone A, Porta E, De Mattei C et al. Multicenter study on hepatitis C virus infection in patients with dilated cardiomyopathy. North Italy Transplant Program (NITP). J Med Virol 1999; 58:116-20.
43. Dalekos GN, Achenbach K, Christodoulou D, Liapi GK, Zervou EK, Sideris DA et al. Idiopathic dilated cardiomyopathy: lack of association with hepatitis C virus infection. Heart 1998;80:270-5.
44. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993;71:12A-16A.
45. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
46. Katsuta Y, Aramaki T, Sekiyama T, Satomura K, Okumura H, Okumura K. Plasma volume contraction in portal hypertension. J Hepatol 1993;17 Suppl 2:S19-S23.
47. Okumura H, Aramaki T, Katsuta Y, Satomura K, Akaike M, Sekiyama T et al. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991;86:46-52.
48. Garcia-Pagan JC, Salmeron JM, Feu F, Luca A, Gines P, Pizcueta P et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994;19:1095-9.
49. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4.